| dc.contributor.author |
Feliu, Jaume |
| dc.contributor.author |
Safont, M. J. |
| dc.contributor.author |
Salud Salvia, Maria Antonieta |
| dc.contributor.author |
Losa, F. |
| dc.contributor.author |
García-Girón, C. |
| dc.contributor.author |
Bosch, Carlos |
| dc.contributor.author |
Escudero, P. |
| dc.contributor.author |
López, R. |
| dc.contributor.author |
Madroñal, C. |
| dc.contributor.author |
Bolaños, M. |
| dc.contributor.author |
Gil, M. |
| dc.contributor.author |
Llombart, A. |
| dc.contributor.author |
Castro-Carpeño, J. |
| dc.contributor.author |
González-Barón, M. |
| dc.date |
2015-07-09T10:39:46Z |
| dc.date |
2010 |
| dc.date |
10000-01-01 |
| dc.identifier |
0007-0920 |
| dc.identifier |
http://hdl.handle.net/10459.1/48457 |
| dc.identifier |
https://doi.org/10.1038/sj.bjc.6605663 |
| dc.identifier.uri |
http://hdl.handle.net/10459.1/48457 |
| dc.description |
BACKGROUND: The efficacy and safety of capecitabine and bevacizumab in elderly patients with metastatic colorectal cancer (mCRC)
considered unsuitable for receiving first-line chemotherapy with an irinotecan or oxaliplatin-based combination were assessed in a
phase II, open, multicentre, uncontrolled study.
METHODS: Treatment consisted of capecitabine 1250 mgm 2 (or 950 mgm 2 for patients with a creatinine clearance of
30–50ml min 1) twice daily on days 1–14 and bevacizumab (7.5 mg kg 1) on day 1 every 3 weeks.
RESULTS: A total of 59 patients aged X70 years with mCRC were enrolled. In an intention-to-treat analysis, the overall response rate
was 34%, with 71% of patients achieving disease control. Median progression-free survival and overall survival were 10.8 months and
18 months, respectively. In all, 32 patients (54%) had grade 3/4 adverse events (AEs), the most common being hand–foot syndrome
(19%), diarrhoea (9%) and deep venous thrombosis (7%). Four patients died because of treatment-related AEs. A relationship was
detected between creatinine clearance p50 ml min 1 and the development of non-bevacizumab-related grade 3/4 AEs. The
incidence of bevacizumab-associated AEs (hypertension, thromboembolic events and proteinuria) was consistent with that of
previous reports in elderly patients.
CONCLUSION: Bevacizumab combined with capecitabine represents a valid therapeutic alternative in elderly patients considered to be
unsuitable for receiving polychemotherapy. |
| dc.language |
eng |
| dc.publisher |
Nature Publishing Group |
| dc.publisher |
Cancer Research UK |
| dc.relation |
Reproducció del document publicat a https://doi.org/10.1038/sj.bjc.6605663 |
| dc.relation |
British Journal of Cancer, 2010, vol. 102, p. 1468-1473 |
| dc.rights |
(c) Cancer Research UK, 2010 |
| dc.rights |
(c) Nature Publishing Group, 2010 |
| dc.rights |
info:eu-repo/semantics/restrictedAccess |
| dc.subject |
capecitabine |
| dc.subject |
bevacizumab |
| dc.subject |
colorectal neoplasms |
| dc.title |
Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer |
| dc.type |
article |
| dc.type |
publishedVersion |
